197 related articles for article (PubMed ID: 35240970)
1. Evaluation of Brain Targeting Potential of Zolmitriptan Mucoadhesive Nanoparticles for Intranasal Drug Delivery.
Jha S; Mishra D
Pharm Nanotechnol; 2022; 10(2):113-124. PubMed ID: 35240970
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic study and brain tissue analysis of Zolmitriptan loaded chitosan nanoparticles in rats by LC-MS method.
Khezri FANZ; Lakshmi CSR; Bukka R; Nidhi M; Nargund SL
Int J Biol Macromol; 2020 Jan; 142():52-62. PubMed ID: 31593739
[TBL] [Abstract][Full Text] [Related]
3. Trans-nasal zolmitriptan novasomes: in-vitro preparation, optimization and in-vivo evaluation of brain targeting efficiency.
Abd-Elal RM; Shamma RN; Rashed HM; Bendas ER
Drug Deliv; 2016 Nov; 23(9):3374-3386. PubMed ID: 27128792
[TBL] [Abstract][Full Text] [Related]
4. Brain targeting efficiency of antimigrain drug loaded mucoadhesive intranasal nanoemulsion.
Abdou EM; Kandil SM; Miniawy HMFE
Int J Pharm; 2017 Aug; 529(1-2):667-677. PubMed ID: 28729175
[TBL] [Abstract][Full Text] [Related]
5. Intranasal mucoadhesive microemulsions of zolmitriptan: preliminary studies on brain-targeting.
Vyas TK; Babbar AK; Sharma RK; Misra A
J Drug Target; 2005 Jun; 13(5):317-24. PubMed ID: 16199375
[TBL] [Abstract][Full Text] [Related]
6. Influence of polymeric microcarriers on the in vivo intranasal uptake of an anti-migraine drug for brain targeting.
Gavini E; Rassu G; Ferraro L; Beggiato S; Alhalaweh A; Velaga S; Marchetti N; Bandiera P; Giunchedi P; Dalpiaz A
Eur J Pharm Biopharm; 2013 Feb; 83(2):174-83. PubMed ID: 23153670
[TBL] [Abstract][Full Text] [Related]
7. A coupled bimodal SPECT-CT imaging and brain kinetics studies of zolmitriptan-encapsulated nanostructured polymeric carriers.
Mandlik SK; Ranpise NS; Mohanty BS; Chaudhari PR
Drug Deliv Transl Res; 2018 Jun; 8(3):797-805. PubMed ID: 29380155
[TBL] [Abstract][Full Text] [Related]
8. Poloxamer 407-based intranasal thermoreversible gel of zolmitriptan-loaded nanoethosomes: formulation, optimization, evaluation and permeation studies.
Shelke S; Shahi S; Jalalpure S; Dhamecha D
J Liposome Res; 2016 Dec; 26(4):313-23. PubMed ID: 26758957
[TBL] [Abstract][Full Text] [Related]
9. Nose to Brain Delivery of Galantamine Loaded Nanoparticles: In-vivo Pharmacodynamic and Biochemical Study in Mice.
Sunena ; Singh SK; Mishra DN
Curr Drug Deliv; 2019; 16(1):51-58. PubMed ID: 30289074
[TBL] [Abstract][Full Text] [Related]
10. Optimization of combinational intranasal drug delivery system for the management of migraine by using statistical design.
Kumar A; Garg T; Sarma GS; Rath G; Goyal AK
Eur J Pharm Sci; 2015 Apr; 70():140-51. PubMed ID: 25676136
[TBL] [Abstract][Full Text] [Related]
11. Development of zolmitriptan transfersomes by Box-Behnken design for nasal delivery: in vitro and in vivo evaluation.
Pitta SK; Dudhipala N; Narala A; Veerabrahma K
Drug Dev Ind Pharm; 2018 Mar; 44(3):484-492. PubMed ID: 29124986
[TBL] [Abstract][Full Text] [Related]
12. Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats.
El-Nabarawy NA; Teaima MH; Helal DA
Drug Des Devel Ther; 2019; 13():3929-3937. PubMed ID: 31819367
[TBL] [Abstract][Full Text] [Related]
13. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.
Charlesworth BR; Dowson AJ; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
CNS Drugs; 2003; 17(9):653-67. PubMed ID: 12828501
[TBL] [Abstract][Full Text] [Related]
14. One should avoid retro-orbital pharmacokinetic sample collections for intranasal dosing in rats: Illustration of spurious pharmacokinetics generated for anti-migraine drugs zolmitriptan and eletriptan.
Patel H; Patel P; Modi N; Shah S; Ghoghari A; Variya B; Laddha R; Baradia D; Dobaria N; Mehta P; Srinivas NR
Eur J Pharm Sci; 2017 Aug; 106():87-93. PubMed ID: 28549679
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial.
Dowson AJ; Charlesworth BR; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
CNS Drugs; 2003; 17(11):839-51. PubMed ID: 12921494
[TBL] [Abstract][Full Text] [Related]
16. Exploring Nose to Brain Nano Delivery for Effective Management of Migraine.
Tanna V; Sawarkar SP; Ravikumar P
Curr Drug Deliv; 2023; 20(2):144-157. PubMed ID: 35366772
[TBL] [Abstract][Full Text] [Related]
17. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE Study.
Gawel M; Aschoff J; May A; Charlesworth BR;
Headache; 2005 Jan; 45(1):7-16. PubMed ID: 15663607
[TBL] [Abstract][Full Text] [Related]
18. Development of zolmitriptan loaded PLGA/poloxamer nanoparticles for migraine using quality by design approach.
Girotra P; Singh SK; Kumar G
Int J Biol Macromol; 2016 Apr; 85():92-101. PubMed ID: 26724690
[TBL] [Abstract][Full Text] [Related]
19. Zolmitriptan nasal spray: advances in migraine treatment.
Syrett N; Abu-Shakra S; Yates R
Neurology; 2003 Oct; 61(8 Suppl 4):S27-30. PubMed ID: 14581655
[TBL] [Abstract][Full Text] [Related]
20. Intranasal zolmitriptan.
Gawel M; Worthington I
Expert Opin Pharmacother; 2005 Jun; 6(6):1019-24. PubMed ID: 15952929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
